The 63rd American Society of Hematology (ASH) annual meeting saw a plethora of updates in lymphoma. While most of them generated a lot of fruitful conversations, some of the breakthroughs have the potential to change practice.
In this roundtable discussion, Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, review the most exciting updates in lymphoma from the 2021 ASH annual meeting and reflect on how the data may impact clinical practice in the UK.
CAR-T therapy in myeloma and lymphoma
CAR-T therapy in AML: challenges and future outlooks
The current state of CAR-T therapy in lymphoma
Myeloma treatment updates from EHA 2022
Updates in classification and risk stratification in MDS
Myeloma 2022: day one highlights
Immune dysregulation and targeting in MDS
The future of CAR-T therapy in ALL
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
Key updates in the treatment and management of MPNs
Addressing unmet needs and future treatment approaches in AL amyloidosis
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
Updates in lymphoma and CLL treatment in the UK
The importance of early intervention and interception in myeloma
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
CAR-T and lymphoma treatment in the UK
Harnessing the power of immunotherapy in myeloma and amyloidosis
The impact of AI and machine learning algorithms in MDS
MMRF-CoMMpass: the genomic basis of myeloma subtypes
Genomics in the age of immuno-oncology
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.